dichloro(1,2-bis(4-hydroxyphenyl)ethylenediamine)platinum ii has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, K; Gust, R; Schertl, S; Schneider, MR; Schönenberger, H; Spruss, T | 1 |
| Amselgruber, W; Humm, A; Schiller, CD; Schneider, MR; Schönenberger, H; Sinowatz, F; Spruss, T | 1 |
2 other study(ies) available for dichloro(1,2-bis(4-hydroxyphenyl)ethylenediamine)platinum ii and Prostatic Neoplasms
| Article | Year |
|---|---|
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Female; Injections, Subcutaneous; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Models, Biological; Neoplasms, Hormone-Dependent; Organ Size; Organoplatinum Compounds; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Uterus | 1993 |
[1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activity.
Topics: Animals; Antineoplastic Agents; Carcinoma; Endocrine Glands; Male; Molecular Structure; Organ Size; Organoplatinum Compounds; Prostatic Neoplasms; Rats; Receptors, Androgen; Receptors, Estrogen; Receptors, Steroid; Recurrence; Testosterone | 1989 |